1. A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions. Issue 6 (8th February 2013) Authors: Halama, B; Hohmann, N; Burhenne, J; Weiss, J; Mikus, G; Haefeli, W E Journal: Clinical pharmacology & therapeutics Issue: Volume 93:Issue 6(2013) Page Start: 564 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CYP2C9 Polymorphism is not a Major Determinant of Bosentan Exposure in Healthy Volunteers. Issue 3 (18th September 2013) Authors: Markert, C; Burhenne, J; Weiss, J; Mikus, G; Haefeli, WE Journal: Clinical pharmacology & therapeutics Issue: Volume 95:Issue 3(2014) Page Start: 250 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Cytochrome P450‐3A Phenotyping Using Midazolam Is Not Altered by OATP1B1 Polymorphisms. Issue 5 (28th February 2013) Authors: Ziesenitz, V C; Weiss, J; Haefeli, W E; Mikus, G Journal: Clinical pharmacology & therapeutics Issue: Volume 93:Issue 5(2013) Page Start: 388 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. O35 Midazolam pharmacokinetics in children with obesity. Issue 6 (17th May 2019) Authors: Gade, C; Sverrisdóttir, E; Dalhoff, K; Sonne, J; Rolighed Christensen, H; Burhenne, J; Mikus, G; Holm, J-C; Meldgaard Lund, T; Holst, H Journal: Archives of disease in childhood Issue: Volume 104:Issue 6(2019) Page Start: e15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P116 Prophylactic use of enoxaparin during bariatric surgery in adolescents with severe obesity. Issue 6 (17th May 2019) Authors: Ziesenitz, V; Vaughns, J; Williams, E; Nadler, E; Mikus, G; van den Anker, J Journal: Archives of disease in childhood Issue: Volume 104:Issue 6(2019) Page Start: e65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Response to "Can CYP3A Activity Be Evaluated for Drug Interaction Using a Nanogram Dose of Probe Drug?": Evaluation of CYP3A Activity With Microdoses of Midazolam. Issue 5 (6th February 2014) Authors: Hohmann, N; Halama, B; Siller, N; Mikus, G; Haefeli, W E Journal: Clinical pharmacology & therapeutics Issue: Volume 95:Issue 5(2014) Page Start: 490 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. The NTCP‐inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics. Issue 2 (21st June 2017) Authors: Blank, A; Eidam, A; Haag, M; Hohmann, N; Burhenne, J; Schwab, M; van de Graaf, SFJ; Meyer, MR; Maurer, HH; Meier, K; Weiss, J; Bruckner, T; Alexandrov, A; Urban, S; Mikus, G; Haefeli, WE Journal: Clinical pharmacology & therapeutics Issue: Volume 103:Issue 2(2018) Page Start: 341 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Vericiguat: a QTc interval study in patients with coronary artery disease. (14th October 2021) Authors: Boettcher, M.-F; Duengen, H.-D; Corcea, V; Donath, F; Fuhr, R; Gal, P; Mikus, G; Trenk, D; Werner, N; Pires, P.V; Maschke, C; Aliprantis, A.O; Besche, N; Becker, C Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗